Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis

Table 2 Relative risk of placenta-mediated complications in studies with and without LDA

	Trials, n	Participants, n	Random effect, Relative risk (95% CI)	P value	I², %
Preeclampsia	10	1758	0.67 (0.50–0.90)	0.009	38
With LDA as the primary intervention	6	1165	0.59 (0.43–0.81)	0.001	45
Without LDA as the primary intervention	4	593	1.52 (0.67–3.46)	0.32	0
Preterm birth	10	1758	0.63 (0.48–0.83)	0.001	0
With LDA as the primary intervention	6	1165	0.62 (0.46–0.84)	0.002	0
Without LDA as the primary intervention	4	593	0.69 (0.33–1.47)	0.34	0
Fetal growth restriction	10	1758	0.72 (0.56–0.91)	0.007	44
With LDA as the primary intervention	6	1165	0.71 (0.55–0.91)	0.007	59
Without LDA as the primary intervention	4	593	0.86 (0.32–2.30)	0.76	1
Placental abruption	6	1046	0.50 (0.19–1.33)	0.16	0
With LDA as the primary intervention	4	738	0.52 (0.19–1.46)	0.21	0
Without LDA as the primary intervention	2	308	0.34 (0.01–8.28)	0.51	-

Data are reported as relative risk and 95% confidence interval in studies with LDA and without LDA. I²: heterogeneity; CI, confidence interval

ISSN: 1471-2393